Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.62 |
| ▸ | PIM1 | P11309 | 7/20 | 0.62 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.62 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989801 | 1.00 | PIM2 (0.62) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3366668 | 1.00 | PIM2 (0.62) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL12990158 | 0.91 | PIM2 (0.60) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3366398 | 0.91 | PIM2 (0.60) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3366393 | 0.91 | PIM2 (0.60) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3362852 | 0.90 | PIM2 (0.51) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3362857 | 0.90 | PIM2 (0.51) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3363434 | 0.86 | PIM2 (0.59) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3366619 | 0.86 | PIM2 (0.62) | PIM2PIM1CSNK2A2CSNK2A1PIM3 | |
| SCHEMBL3366614 | 0.86 | PIM2 (0.62) | PIM2PIM1CSNK2A2CSNK2A1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010148351-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | PIM2 1/4885PIM1 2/4885CSNK2A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.